Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
MetadataShow full item record
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Version of record
Small cell lung cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Drug Resistance, Neoplasm
Positron Emission Tomography Computed Tomography
Small Cell Lung Carcinoma
License start date
Lung Cancer, 2017, 111 pp. 65 - 68
Showing items related by title, author, creator and subject.
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Popat, S; Mellemgaard, A; Reck, M; Hastedt, C; Griebsch, I (2017-02-27)PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: ...
Discovery of small molecules as anticancer agents: the role of the medicinal chemist in the discovery of new cancer therapeutics McDonald, T; Bavetsias, V (2005)Discovery of small molecules as anticancer agents: the role of the medicinal chemist in the discovery of new cancer therapeutics
Stratton, M (NATURE PUBLISHING GROUP, 2010-01)Cancer is driven by mutation. Worldwide, tobacco smoking is the principal lifestyle exposure that causes cancer, exerting carcinogenicity through \ensuremath>60 chemicals that bind and mutate DNA. Using massively parallel ...